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ABSTRACT Left untreated, inhalation anthrax is usually fatal. Vegetative forms of Bacillus anthracis 22 
survive in blood and tissues during infection due to elaboration of a protective poly-γ-D-glutamic 23 
acid (PDGA) capsule that permits uncontrolled bacterial growth in vivo, eventually leading to 24 
overwhelming bacillosis and death. As a measure to counter threats from multi-drug-resistant 25 
strains, we are evaluating the prophylactic and therapeutic potential of the PDGA depolymerase 26 
EnvD, a stable and potent enzyme which rapidly and selectively removes the capsule from the 27 
surface of vegetative cells. Repeated intravenous administration of 10 mg/kg recombinant EnvD to 28 
mice infected with lethal doses of B. anthracis Ames spores by inhalation prevented the emergence 29 
of symptoms of anthrax and death; all animals survived the five day treatment period and 70% 30 
survived to the end of the 14 day observation period. In contrast to sham-treated animals, the lungs 31 
and spleen of rEnvD-dosed animals were free of gross pathological changes. We conclude that rEnvD 32 
has potential as an agent to prevent the emergence of inhalation anthrax in infected animals and is 33 
likely to be effective against drug resistant forms of the pathogen. 34 
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INTRODUCTION 48 
Bacillus anthracis featured in offensive weapons programs in the USA and former Soviet Union 49 
during the last century (1) and has been identified by the World Health Organization, the United 50 
Nations and the Working Group on Civilian Defense (WGCB) as a pathogen of great concern. The 51 
WGCB has highlighted a limited number of microorganisms that could cause infections in sufficient 52 
numbers to cripple a city or region and B. anthracis is one of the most serious of such threat agents 53 
(2).  Their spores are able to survive in hostile environments for many decades and, in aerosolized 54 
form, can travel significant distances on prevailing winds, disseminating over a wide area. Accidental 55 
release of anthrax spores as an aerosol from a military facility in Sverdlovsk in 1979 resulted in at 56 
least 79 cases of anthrax and 68 deaths, demonstrating its lethal potential (3). These traits define B. 57 
anthracis as a potential threat agent, attractive to both rogue states and terrorist groups, and a 58 
cause of human and animal disease globally. The vegetative bacilli release toxin complexes that 59 
cause hemorrhage, edema and necrosis and are protected from host innate defenses by a capsule 60 
comprised of poly-γ-D-glutamic acid (PDGA) (4). In inhalation anthrax, endospores gain access to the 61 
alveolar spaces and are ingested by macrophages; they are then transported to regional lymph 62 
nodes where spore germination occurs after a variable period of dormancy (4, 5). Toxin-mediated 63 
clinical symptoms typically arise soon after the onset of rapid bacillary growth (2). 64 
 Effective treatment requires prompt and aggressive antibiotic therapy; a fluoroquinolone 65 
and an agent that inhibits protein synthesis such as linezolid are currently recommended by the 66 
Centers for Disease Control and Prevention (6). The consensus approach to prophylaxis and 67 
treatment of inhalation anthrax could be compromised by the release of B. anthracis carrying 68 
engineered antibiotic resistance genes and occasional reports have emerged of naturally occurring 69 
strains resistant to currently useful antibiotics (7, 8). Clearly, new agents or novel therapeutic and 70 
prophylactic modalities should be developed as a part of a comprehensive preparedness strategy. 71 
We previously demonstrated that parenteral administration of a capsule depolymerase with the 72 
capacity to rapidly and selectively remove the protective capsule from the bacterial surface can 73 
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resolve potentially lethal Escherichia coli infection in the neonatal rat (9, 10). Systemic anthrax is an 74 
attractive candidate for this approach as infections are attributable to a single, phylogenetically 75 
homogeneous bacterial species, all strains elaborate the unique PDGA capsule essential for 76 
pathogenesis (11) and hydrolysis of the outermost layer of the bacilli would confound attempts to 77 
circumvent antibiotic chemotherapy by the introduction of antibiotic resistance genes into B. 78 
anthracis. Here we report that early intravenous administration of rEnvD, a recombinant PDGA 79 
hydrolase elaborated by a consortium culture of soil bacteria, is able to prevent anthrax in mice 80 
infected by the inhalation route. 81 
 82 
MATERIALS AND METHODS 83 
Bacteria. B. anthracis Ames (NR-2324; pXO1+, pXO2+) was obtained from the Biodefense and 84 
Emerging Infections Research Resources Repository (Manassas, VA). Spores were prepared by fed 85 
batch culture in a 2 l bioreactor for 26 h at 37°C with stirring at 400 rpm, collected by centrifugation 86 
and washed in sterile distilled water. For spore challenge tests, suspensions (8 × 109 CFU/ml) were 87 
prepared in sterile water.  Bacillus licheniformis ATCC 9945a was purchased from the American Type 88 
Culture Collection and grown in Medium E containing 615 µM MnSO4 in an orbital incubator (200 89 
orbits/min) at 37°C (12).  90 
Recombinant EnvD. The enzyme was expressed, refolded and purified as described previously (12). 91 
Endotoxin was removed using Proteus Endotoxin Removal Columns (Abd Serotec, Oxford, UK) and 92 
removal confirmed with the Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher, 93 
Rockford, USA). Purified rEnvD was stored in 20 mM Tris (pH 8.5) at -20°C until required. 94 
Impact of rEnvD on bacterial viability. A culture (50 ml) from a single, heavily mucoid colony of B. 95 
licheniformis 9945a was grown to OD600 0.6 and examined by light microscopy to ensure only 96 
vegetative bacilli were present. Two aliquots of 1 ml were removed and rEnvD added to one aliquot 97 
to give a final protein concentration of 1µg/ml. An equal volume of phosphate buffered saline (PBS) 98 
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was added to the second. Both samples were incubated at 37°C for 15 min, serially diluted in PBS 99 
and plated onto Luria-Bertani agar. Plates were incubated at 37°C for 16 h and bacteria enumerated.   100 
Stability of rEnvD in serum. Aliquots of rEnvD (final concentration 100 nM; in 1.6 ml Eppendorf 101 
tubes) were incubated at 37°C in serum from BALB/c mice (Sigma; total volume 200 µl) for up to 24 h 102 
and EnvD activity determined at regular intervals by Förster resonance energy transfer (FRET) 103 
utilizing the fluorescently labelled synthetic peptide substrate 5-FAM-(D-Glu-γ-)5-K(QXLTM520)-NH2 as 104 
previously described (12). Two tubes were used for each time point, to provide duplicate readings. In 105 
some experiments heat-inactivated (56°C, 30 min) serum was used and some assays were conducted 106 
in the presence of Roche complete protease inhibitor cocktail (Roche, Basel, Switzerland) at 107 
concentrations specified by manufacturer’s guidelines. 108 
Serum half-life. Pairs of female adult BALB/c mice were dosed with 10 mg/kg rEnvD in 180 µl 20 mM 109 
Tris pH 8.5 by tail vein injection. Paired animals were sacrificed over a 24 h period, blood withdrawn 110 
by cardiac puncture and serum obtained. Serum was diluted twofold with 0.1 M Tricine, 0.1% 111 
CHAPS, pH 8.5 to a final volume of 200 µl and 100 μl transferred to each well of a black 96 well 112 
microtiter plate. All assays were run in duplicate. rEnvD activity was measured using the FRET assay 113 
described above with the exception that fluorescence was measured over a 4 min period. The 114 
concentration of enzyme in each sample was determined using a standard curve prepared in mouse 115 
serum. Area under the curve (AUC) was calculated by GraphPad Prism (GraphPad Software Inc., La 116 
Jolla, CA) using the trapezoid rule. 117 
Infection of mice with B. anthracis. All animal studies were carried out in accordance with the UK 118 
Animals (Scientific Procedures) Act, 1986 and the Codes of Practice for the Housing and Care of 119 
Animals used in Scientific Procedures, 1989 following approval by the local ethical committee and 120 
the UK Home Office. Female BALB/c mice (minimum age 10 weeks; approximate body weight 20 g; 121 
food and water available ad libitum) were obtained from Charles River (Canterbury, UK) and infected 122 
by aerosol (13). Groups of ten mice were challenged with 10-50 minimum lethal doses (LD50 6 × 104 123 
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CFU; presented dose ~1.45 × 106 CFU) of B. anthracis spores with the AeroMP-Henderson apparatus. 124 
The challenge aerosol was generated using a six-jet Collison nebuliser (BGI Inc., Waltham, MA), the 125 
aerosol mixed with conditioned air in the spray tube and delivered to the nose of each animal 126 
through an exposure tube in which non-anesthetized mice were held in restraint tubes. Samples of 127 
the aerosol were obtained with an AGI30 glass impinger (Ace Glass Inc., Vineland, NJ) and the mean 128 
particle size determined with an aerodynamic particle sizer (TSI Instruments Ltd., High Wycombe, 129 
UK); these processes were controlled and monitored from an AeroMP management platform (Biaera 130 
Technologies, Hagerstown, MD) . All-glass impinger samples were titrated by serial dilution and 131 
plated on trypticase soy agar prior to incubation at 37°C for 16-24 h. 132 
Intravenous (i.v.) administration of rEnvD was initiated 12 h after spore challenge. The 133 
dosing regimen was guided by the stability of the enzyme in commercial mouse serum and by the 134 
rate of clearance of rEnvD from the circulation of adult female BALB/c mice. Each mouse received 135 
rEnvD (0.5-10 mg/kg) by injection at regular intervals up to 120 h after spore challenge; groups were 136 
comprised of ten individual animals. Control mice received i.v. injections of PBS (180 µl) at these 137 
time points. Additional groups of ten mice received oral doses of ciprofloxacin (118 mg/kg every 12 h 138 
for 14 days). Animals were monitored and assigned a clinical score at least twice daily up to 14 days 139 
after spore challenge and at least four times daily during critical periods (13). Clinical scores were 140 
based on severity of symptoms (ruffled fur, closed eyes, arched back, immobility, weight loss). 141 
Animals surpassing a threshold score were euthanized humanely by pentobarbital overdose. 142 
Surviving mice from each group were euthanized at day 14 after challenge. Post mortem, blood, lung 143 
and spleen samples were taken for enumeration of bacterial load: tissues were weighed and 144 
homogenized in sterile water using a Precellys24 tissue homogenizer (Bertin Technologies, 145 
Villeurbanne, France), the homogenates serially diluted in sterile water, plated onto trypticase soy 146 
agar and the plates incubated at 37°C for 16-24 h before enumeration. Further lung and spleen 147 
samples were placed in 10% neutral-buffered formalin for pathological evaluation. An additional 148 
group of ten mice was employed to evaluate pathological changes six days after spore challenge; 149 
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animals were culled 24 h after receiving their final dose of rEnvD on day five and blood and tissue 150 
samples removed. Kaplan-Meier log rank test was used to determine the significance of differences 151 
in survival between groups of animals and GraphPad Prism software (GraphPad, La Jolla, USA) was 152 
employed. For histological evaluation, formalin-fixed tissue samples were processed to paraffin wax 153 
and 3-5 µm sections cut and stained with hematoxylin and eosin. Sections were examined by light 154 
microscopy and evaluated subjectively. Slides were randomized by a third party before microscopic 155 
examination to avoid prior knowledge of group or treatment. 156 
 157 
RESULTS 158 
rEnvD is a promising candidate for in vivo attenuation of B. anthracis capsule expression. 159 
Unusually, envD resides on the genome of a strain of Pusillimonas nortemannii but the enzyme is 160 
only produced when the bacteria are co-cultured with a strain of Pseudomonas fluorescens (12, 14). 161 
rEnvD showed strong sequence homology to bacterial dienelactone hydrolases and its enzymatic 162 
activity is restricted to the hydrolysis of γ-linkages in D- and L-glutamic acid-containing polymers (kcat 163 
[h-1] 72.6; km [µM] 0.65; kcat/km [M-1 s-1 x 104] 3.08 at 37oC). The enzyme retained enzymatic activity 164 
after accelerated storage at 37oC for 30 days and completely removed the capsule from B. anthracis 165 
Pasteur strain within 5 min at 37oC (12). Exposure of Bacillus licheniformis ATCC 9945a (induced to 166 
elaborate a PDGA polymer) to rEnvD resulted in rapid stripping of the capsule (12) but the viability of 167 
this surrogate strain was not significantly altered (2.5 × 108 to 2.9 × 108 CFU/ml over 15 min; n=6, 168 
Student’s t >0.05).   169 
 There is limited capacity for repeated parenteral injections in small animals. To guide the 170 
design of dosing regimens for the administration of rEnvD to infected BALB/c mice, we determined 171 
the retention of depolymerase activity in mouse serum and the serum half-life (t½) following 172 
intravenous (i.v.) administration. The reduction in rEnvD activity following incubation at 37oC in 173 
murine serum as determined by FRET assay (12) followed first-order kinetics with t½ of 177 min (Fig. 174 
1A); approximately 20% of activity remained after 8 h incubation. Neither heat inactivation of serum 175 
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nor the presence of protease inhibitors had any impact on the rate of reduction of activity. 176 
Elimination of rEnvD from the blood circulation of BALB/c mice was biphasic, with an initial rapid 177 
decrease in serum concentration (0.5 h to 1 h) followed by a slower elimination phase (2 h to 24 h) 178 
characteristic of first order kinetics (Fig. 1B). This elimination profile is typical of agents administered 179 
by the intravenous route (15); a rapid decrease in serum concentration due to distribution from the 180 
central circulation into the peripheral body tissues (alpha phase) followed by a gradual decrease in 181 
plasma concentration attributable to metabolism and excretion of the drug (beta phase). AUC was 182 
determined as 118 nM.h/l. Based on this data, we established a dosing regimen in which mice 183 
received rEnvD (0.5-10 mg/kg body weight) by i.v. injection 12 h, 24 h, 48 h, 72 h, 96 h and 120 h 184 
after spore challenge. 185 
rEnvD administration prevents inhalation anthrax in aerosol-challenged mice. Typically, all animals 186 
in sham-treated (PBS) control groups met humane endpoints within 72 h (median time to death 48 187 
h) whereas all mice treated with 10 mg/kg of rEnvD survived the treatment period (P<0.0001; log 188 
rank) (Fig. 2A). Nine days after termination of treatment, 70% of rEnvD-treated mice had survived 189 
(P<0.0001, compared to control animals). The protective effect of rEnvD was reflected in the 190 
comparative health status of the mice: abnormal clinical signs were absent from rEnvD-treated 191 
animals during the five-day period of enzyme administration (Fig. 2B). At six and fourteen days post-192 
challenge and in contrast to controls, bacteria were not cultured from the blood or spleen of 193 
surviving rEnvD-treated mice from the tissue group; sham-treated mice were found to carry a high B. 194 
anthracis bioburden in the blood (mean 2.4 × 104 CFU/ml) and spleen (mean 5.84 × 104 CFU/mg) at 195 
time of post mortem examination (based on severity threshold score). High numbers of viable 196 
bacteria were also present in the lung of sham-treated animals at the same time point (mean 1.37 × 197 
105 CFU/mg). In comparison to controls, a significant (P=0.006311) reduction in the lung bioburden 198 
was noted in EnvD-treated animals six days after spore challenge (mean 1.55 × 102 CFU/mg) 199 
compared to controls and a lower number (mean 2.07 × 101 CFU/mg) were present in the lung of 200 
surviving animals 14 days after challenge (Fig. 3).  201 
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Microscopic changes referable to infection with B.anthracis were observed in the lung and 202 
spleen of all control animals. In the lung, there was prominent pulmonary congestion and patchy 203 
haemorrhage, expanding septal cavities and numerous bacilli located in alveolar spaces, walls and 204 
within vessel lumena (bacteremia) (Fig. 4A).  In the spleen, numerous bacilli within the red pulp 205 
sinusoids and vascular lumena were present in these control animals (data not shown).  Further, 206 
splenic white pulp contained prominent degeneration and loss of lymphocytes, characterized by 207 
nuclear fragmentation and cellular paucity. In contrast, animals receiving rEnvD and surviving until 208 
study endpoints were found to be clear of gross pathological changes and bacilli were not visible 209 
within lung (Fig. 4B) or spleen tissue.  210 
Experiments with 5 mg/kg rEnvD dosed over three days also demonstrated a high degree of 211 
protection from anthrax infection (100% survival at 3 days; 60% survival at 14 days) but 0.5 mg/kg 212 
rEnvD did not prevent the emergence of clinical symptoms and death; rEnvD administered for five 213 
days provided better protection than orally dosed ciprofloxacin administered by the oral route 214 
throughout the fourteen day period (Fig. 2C & D).  215 
 216 
DISCUSSION  217 
This study provides clear evidence that prompt serial i.v. administration of small quantities 218 
of EnvD prevents the onset and progression of inhalation anthrax in a robust murine model of 219 
invasive disease. Even though the strain employed in this study is highly toxigenic, removal of the 220 
capsule during the early stages of infection appears sufficient to confound the pathogenic potential 221 
of the invading bacteria and further supports the key role of the protective PDGA capsule in anthrax 222 
pathogenesis (4, 11), highlighting the requisite nature of the capsule for in vivo dissemination of 223 
vegetative bacilli. The study also adds to growing evidence that prophylaxis and treatment of severe 224 
systemic infections can be realised by agents that do not kill the target bacterial population per se 225 
but modify the phenotype of the pathogen in a way that is beneficial to the host (16). Further, this 226 
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approach has the potential to deliver exquisitely selective therapeutics that are unaffected by the 227 
presence of antibiotic resistance mechanisms. 228 
Treatment of bacterial infections with capsule depolymerases was first explored over 80 229 
years ago by Dubos, Avery and colleagues at the Rockefeller Institute for Medical Research. They 230 
used an enzyme preparation from cultures of a peat soil bacterium to selectively remove the 231 
polysaccharide capsule from the surface of type III pneumococci (17), the pathogen’s principle 232 
means of defense against immune attack. Intraperitoneal administration of enzyme extracts to mice 233 
prior to challenge with type III pneumococci gave rise to type III-specific protection (18), i.v. 234 
administration to rabbits with type III dermal infections resulted in early termination of the normally 235 
fatal infection (19) and the enzyme prevented dissemination, sterilized the blood and promoted 236 
early recovery in non-human primates infected by the intratracheal and intrabronchial routes (20). 237 
In addition to our previous work on systemic neonatal E. coli infections (9, 10), capsule 238 
depolymerases have been shown to resolve potentially lethal experimental Klebsiella pneumoniae 239 
K1 infections in mice (21). 240 
Recently, other attempts have been made to exploit PDGA depolymerases as anti-anthrax 241 
therapeutics. CapD is a γ-glutamyltranspeptidase elaborated by B. anthracis and catalyzes the 242 
attachment of PDGA to peptidoglycan, but also functions as a depolymerase, effecting the release of 243 
diffusible PDGA fragments from the surface of producer strains (22). CapD mediates removal of the 244 
capsule and induces macrophage uptake and neutrophil killing in vitro (23). Intraperitoneal co-245 
injection of CapD and vegetative B. anthracis Ames bacteria afforded some protection against 246 
infection in mice but no significant protection could be demonstrated when the enzyme was 247 
administered after challenge with Ames spores (24), almost certainly due to the labile nature of 248 
CapD (12, 20). rEnvD is a far more robust enzyme (12) and a better candidate for therapeutic 249 
development.  250 
Current evidence suggests that although the toxin complex undoubtedly plays a vital role in 251 
anthrax pathogenesis, probably by suppression of the immune response in early stages of the 252 
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disease, death occurs from overwhelming bacteremia and sepsis due to uncontrolled bacterial 253 
proliferation and release of pro-inflammatory mediators (25). Thus, a therapeutic window may be 254 
available if treatment is initiated before extensive bacterial division occurs in the blood. Our results 255 
support this hypothesis: depolymerase administration initiated 12 h after aerosol challenge provided 256 
significant protection against systemic anthrax and prevented bacteremia and dissemination of 257 
bacilli to the spleen. This concurs with a previous report that the capsule is essential for 258 
hematogenous bacillary spread, as capsule negative mutants did not migrate to the spleen in 259 
experimental infections (11). In the current study, deaths generally occurred following cessation of 260 
treatment. Viable bacteria were present in the lung of rEnvD-treated mice after the treatment 261 
period and animals that subsequently succumbed to infection almost certainly died due to delayed 262 
germination of latent spores and after enzyme had been cleared from the blood circulation. B. 263 
anthracis spores are known to persist in the lung for extended periods: for example, latent spores 264 
have been isolated from the lung tissue of non-human primates months after initial exposure (26). 265 
The size of the mouse restricts the number of i.v. injections that can be given over a relatively short 266 
period of time and this issue will be addressed using larger species such as the rabbit. In addition, 267 
the mouse is particularly susceptible to death from systemic anthrax due to uncontrolled in vivo 268 
bacterial growth and a high quantitative level of bacteremia (27), factors which do not favour an 269 
anti-capsule therapeutic strategy. The relative susceptibility of humans to toxemia and infection in 270 
anthrax is poorly documented but the rabbit is used as an equivalent to human infection (27) and 271 
examination of rEnvD in this species will be an important next step. 272 
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FIG. 1 In vitro stability in serum and elimination of rEnvD from the circulation of BALB/c mice. A: 380 
Stability of rEnvD in BALB/c mouse serum; 100 nM of enzyme was incubated at 37oC in serum and 381 
activity determined by FRET assay (12). Enzyme activity in relative fluorescent units was converted to 382 
concentration of active enzyme by comparison to a standard curve.  Error bars represent the range 383 
of three separate determinations; t1/2 in serum of rEnvD was 2.95 h (177 min). B: rEnvD in serum 384 
obtained from mice intravenously dosed with 10 mg/kg rEnvD. Serum was obtained by terminal 385 
bleed and enzyme activity determined by FRET assay; Serum concentration (Cp) of rEnvD was 386 
obtained by comparison to a standard curve. Error bars represent the range of three separate 387 
determinations performed in duplicate; t1/2 was calculated by determination of the elimination rate 388 
constant (Ke) and transformation of data to the natural log (ln) to produce a line of best fit for each 389 
phase with the slope equal to Ke: t 1/2 = ln(2)/Ke. The t1/2 for the initial alpha phase between 0.5 h and 390 
1 h was 0.22 h (13 min) and for the beta phase between 2 h and 24h was 2.71 h (163 min). 391 
FIG. 2 Impact of intravenous administration of rEnvD on inhalation anthrax in mice. Combined 392 
Kaplan-Meier survival plots (A, C) and cumulative mean clinical observation scores (B, D) for rEnvD-393 
dosed, infected BALB/c mice. Mice were infected with B. anthracis Ames on day 0 by aerosol 394 
followed by tail vein administration of either 10 mg/kg rEnvD or PBS vehicle (A, B) or 0.5 mg/kg 395 
rEnvD (C, D) at the times indicated by arrows.  Ciprofloxacin (118 mg/kg) was also administered 396 
orally for 14 days (C, D). Clinical observations were scored as described (13) and were based on 397 
severity of symptoms (ruffled fur, closed eyes, arched back, immobility, weight loss). 398 
FIG. 3 B. anthracis (CFU/mg tissue) in the spleen and lung of mice following rEnvD or PBS 399 
administration by the intravenous route; n=7-10, mean ±1 SD. PBS controls were culled when the 400 
clinical score reached threshold levels, as the animals were then close to death (13). Tissues were 401 
weighed and homogenized in sterile water, the homogenates serially diluted in sterile water, plated 402 
onto trypticase soy agar and the plates incubated at 37°C for 16-24 h. 403 
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FIG. 4 Pathology of lung tissue six days after inhalation of spores. Samples were fixed in 10% neutral-404 
buffered formalin, processed to paraffin wax, sectioned to 3-5 µm, stained with HE and examined by 405 
light microscopy. Slides were randomized by a third party before microscopic examination to avoid 406 
prior knowledge of group or treatment. A: From animals receiving only PBS vehicle; region shows 407 
iatrogenic thickening of the alveolar walls due to the collapsed nature of the tissue. Arrows indicate 408 
bacilli located in alveolar spaces; Ve, vessel lumena. B: From animals receiving 10 mg/kg rEnvD over 409 
5 days; image from region of inflated lung. 410 
